Clinical Trial Update: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. [Phase 2]

View source ↗

Summary

Phase 2 study of everolimus (RAD001) in relapsed/refractory Hodgkin lymphoma after high-dose chemotherapy/autologous stem cell transplant or after gemcitabine-,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-04-06